European decision on embryo stem cells may undermine medical research
This article was originally published in Clinica
Executive Summary
In an opinion published on 18 October, the European Court of Justice has ruled that a process which involves removal of a stem cell from a human embryo at the blastocyst stage, entailing the destruction of that embryo, is not patentable. The ruling concerns a method invented by Oliver Bruestle of the University of Bonn for converting human embryonic stem cells into nerve cells, and upholds an earlier legal opinion of Advocate General Yves Bott.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.